Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.

Kunito S, Takakura S, Nagata C, Saito M, Yanaihara N, Yamada K, Okamoto A, Sasaki H, Ochiai K, Tanaka T.

J Obstet Gynaecol Res. 2012 Dec;38(12):1367-75. doi: 10.1111/j.1447-0756.2012.01884.x. Epub 2012 May 28.

PMID:
22639843
2.

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T.

Oncol Rep. 2006 Dec;16(6):1301-6.

PMID:
17089053
3.

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.

Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y.

Int J Clin Oncol. 2007 Aug;12(4):256-60. Epub 2007 Aug 20.

PMID:
17701003
4.

Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.

Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.

Int J Gynecol Cancer. 2010 Feb;20(2):240-7.

PMID:
20169667
5.

Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.

Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A.

Int J Gynecol Cancer. 2014 Sep;24(7):1181-9. doi: 10.1097/IGC.0000000000000178.

PMID:
25010038
6.

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.

Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D.

J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.

PMID:
27400948
7.

Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.

Takada T, Iwase H, Iitsuka C, Nomura H, Sakamoto K, Omatsu K, Takeshima N, Takizawa K.

Int J Gynecol Cancer. 2012 May;22(4):573-8. doi: 10.1097/IGC.0b013e31823fd413.

PMID:
22398705
8.

Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.

Takakura S, Saito M, Ueda K, Motegi M, Takao M, Yamada K, Okamoto A, Niimi S, Sasaki H, Tanaka T, Ochiai K.

Int Surg. 2007 Jul-Aug;92(4):202-8.

PMID:
18050828
9.

Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.

Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K, Tanaka K.

Gynecol Oncol. 2005 Jun;97(3):893-7.

PMID:
15894369
10.

Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.

Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T, Nagata I.

Oncol Rep. 2000 Mar-Apr;7(2):327-31.

PMID:
10671681
11.

[A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].

Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T.

Gan To Kagaku Ryoho. 2008 Jul;35(7):1243-5. Japanese.

PMID:
18633273
12.

Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.

Kajiyama H, Shibata K, Suzuki S, Ino K, Kawai M, Nagasaka T, Nawa A, Kikkawa F.

Gynecol Obstet Invest. 2011;72(4):252-6. doi: 10.1159/000327924. Epub 2011 Oct 25.

PMID:
22041903
13.

A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).

Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):259-63. doi: 10.1016/j.ejogrb.2013.06.035. Epub 2013 Jul 20.

PMID:
23880598
14.

Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.

Higashi M, Kajiyama H, Shibata K, Mizuno M, Mizuno K, Hosono S, Kawai M, Nakanishi T, Nagasaka T, Kikkawa F.

Gynecol Oncol. 2011 Dec;123(3):474-8. doi: 10.1016/j.ygyno.2011.08.036. Epub 2011 Sep 28.

PMID:
21955484
15.

Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.

Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42. Epub 2007 Dec 13.

PMID:
18081792
16.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

17.

[Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].

Hirakawa H, Futagami M, Yokoyama Y, Hakamada K, Mizunuma H.

Gan To Kagaku Ryoho. 2011 May;38(5):857-60. Japanese.

PMID:
21566454
18.

Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?

Mizuno M, Kajiyama H, Shibata K, Mizuno K, Yamamuro O, Kawai M, Nakanishi T, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2012 Sep;22(7):1143-9. doi: 10.1097/IGC.0b013e31825c7cbe.

PMID:
22801028
19.

A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.

Shimizu Y, Umezawa S, Hasumi K.

Ann Acad Med Singapore. 1998 Sep;27(5):650-6.

PMID:
9919334
20.

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T.

Br J Cancer. 2006 May 22;94(10):1369-74.

Supplemental Content

Support Center